Kedrion SpA:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Kedrion SpA - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C5144
◆発行会社(調査会社):GlobalData
◆発行日:2018年9月
◆ページ数:24
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イタリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Kedrion SpA (Kedrion) collects and fractionates blood plasma to develop, produce and distribute plasma-derived therapies. The company’s products are used for the treatment of rare and serious disorders such as hemophilia, immune deficiency and neurological disorders. It also offers products for the treatment of orphan diseases. Kedrion also offers contract manufacturing services, technology transfer services and biological safety center services. The company works in partnership with Italian National Health Service to achieve self-sufficiency in plasma-derived therapies. It has manufacturing plants in Italy, Hungary and the US. The company has operational presence in Asia, Europe, North America and South America. Kedrion is headquartered in Barga, Lucca, Italy.

Kedrion SpA – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Kedrion SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Kedrion SpA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Kedrion SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Kedrion SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Kedrion SpA, Medical Devices Deals, 2012 to YTD 2018 10
Kedrion SpA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Kedrion SpA, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Kedrion Acquires RhoGAM Line Of Products From Ortho-Clinical Diagnostics 12
Partnerships 13
National Immunobiological, Pharmstandard and Kedrion Biopharma form Joint Venture 13
Biotest Pharma Enters into Distribution Agreement with Kedrion Biopharma 14
Licensing Agreements 15
United Biotech Enters into Licensing Agreement with Kedrion 15
Debt Offering 16
Kedrion Raises USD397 Million in Public Offering of 3% Bonds Due 2022 16
Kedrion Raises USD514 Million in Private Placement of Bonds 17
Acquisition 18
Kedrion Completes Acquisition Of Somerset Labs From Ortho-Clinical Diagnostics 18
Fondo Strategico Italiano Acquires 18.6% Stake In Kedrion From Sestant For US$188 Million 19
Kedrion SpA – Key Competitors 20
Kedrion SpA – Key Employees 21
Kedrion SpA – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Appendix 24
Methodology 24
About GlobalData 24
Contact Us 24
Disclaimer 24

List of Tables
Kedrion SpA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Kedrion SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Kedrion SpA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Kedrion SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Kedrion SpA, Deals By Therapy Area, 2012 to YTD 2018 8
Kedrion SpA, Medical Devices Deals, 2012 to YTD 2018 10
Kedrion SpA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Kedrion Acquires RhoGAM Line Of Products From Ortho-Clinical Diagnostics 12
National Immunobiological, Pharmstandard and Kedrion Biopharma form Joint Venture 13
Biotest Pharma Enters into Distribution Agreement with Kedrion Biopharma 14
United Biotech Enters into Licensing Agreement with Kedrion 15
Kedrion Raises USD397 Million in Public Offering of 3% Bonds Due 2022 16
Kedrion Raises USD514 Million in Private Placement of Bonds 17
Kedrion Completes Acquisition Of Somerset Labs From Ortho-Clinical Diagnostics 18
Fondo Strategico Italiano Acquires 18.6% Stake In Kedrion From Sestant For US$188 Million 19
Kedrion SpA, Key Competitors 20
Kedrion SpA, Key Employees 21
Kedrion SpA, Subsidiaries 22

List of Figures
Kedrion SpA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Kedrion SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Kedrion SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Kedrion SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Kedrion SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Kedrion SpA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Kedrion SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Kedrion SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Kedrion SpA, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Kedrion SpA:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • BOE Technology Group Co Ltd:企業の戦略・SWOT・財務情報
    BOE Technology Group Co Ltd - Strategy, SWOT and Corporate Finance Report Summary BOE Technology Group Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Constant Contact, Inc.:企業の戦略・SWOT・財務分析
    Constant Contact, Inc. - Strategy, SWOT and Corporate Finance Report Summary Constant Contact, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • MMC Corp Bhd (MMCCORP):企業の財務・戦略的SWOT分析
    Summary MMC Corp Bhd (MMC) is an investment holding company which carries out mining, mineral exploration and construction services. It operates through ports and logistics, energy and utilities, engineering and industrial development divisions. The company offers containers, bulk and breakbulk, liq …
  • The Arag Group
    The Arag Group - Strategy, SWOT and Corporate Finance Report Summary The Arag Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Titan Logix Corp (TLA):企業の財務・戦略的SWOT分析
    Summary Titan Logix Corp (Titan) is a technology company that offers research and development, manufacturing and marketing of advanced technology fluid management solutions. The company's products include stationary guided wave radar gauges for level measurement and overfill prevention, for use in t …
  • Eurocommercial Properties NV:企業の戦略・SWOT・財務分析
    Eurocommercial Properties NV - Strategy, SWOT and Corporate Finance Report Summary Eurocommercial Properties NV - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Dell Technologies Inc (DVMT)-医療機器分野:企業M&A・提携分析
    Summary Dell Technologies, Inc. (Dell), formerly Dell Inc., is a provider of desktop personal computers, software and peripherals. The company designs, develops, manufactures, markets, sells and supports information technology infrastructure such as laptops, desktops, mobiles, workstations, storage …
  • Alexza Pharmaceuticals Inc:企業の戦略的SWOT分析
    Alexza Pharmaceuticals Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Linamar Corporation:企業の戦略・SWOT・財務情報
    Linamar Corporation - Strategy, SWOT and Corporate Finance Report Summary Linamar Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Lebara Group:企業の戦略的SWOT分析
    Lebara Group - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Sun BioPharma Inc (SNBP):製薬・医療:M&Aディール及び事業提携情報
    Summary Sun BioPharma Inc (Sun BioPharma), formerly Cimarron Medical Inc is a biopharmaceutical company that develops disruptive therapeutics for treatment of pancreatic cancer and pancreatitis. The company’s pipeline products include SBP-101, SBP-102 and SBP-103. Its SBP-101 produces superior anti- …
  • Trimble Inc:企業の戦略・SWOT・財務情報
    Trimble Inc - Strategy, SWOT and Corporate Finance Report Summary Trimble Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Cynosure Inc:医療機器:M&Aディール及び事業提携情報
    Summary Cynosure Inc (Cynosure), a subsidiary of Hologic Inc, is a developer, manufacturer and supplier of light-based aesthetic and medical treatment systems. Its products facilitate non-invasive body contouring, skin revitalization and scar reduction, cellulite reduction, hair removal, gynecologic …
  • Credit Suisse Group AG:戦略・SWOT・企業財務分析
    Credit Suisse Group AG - Strategy, SWOT and Corporate Finance Report Summary Credit Suisse Group AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • RespireRx Pharmaceuticals Inc (RSPI):製薬・医療:M&Aディール及び事業提携情報
    Summary RespireRx Pharmaceuticals Inc (RespireRx), formerly Cortex Pharmaceuticals, Inc., focuses on the discovery, development and commercialization of innovative products for the treatment of various respiratory disorders. It has two drug platforms, each with a clinical stage compound directed at …
  • Whiting Petroleum Corporation:企業の戦略・SWOT・財務情報
    Whiting Petroleum Corporation - Strategy, SWOT and Corporate Finance Report Summary Whiting Petroleum Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Bausch & Lomb Incorporated:企業のM&A・事業提携・投資動向
    Bausch & Lomb Incorporated - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Bausch & Lomb Incorporated Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acqui …
  • UniQure NV (QURE):製薬・医療:M&Aディール及び事業提携情報
    Summary UniQure NV (UniQure) develops and markets gene therapy products. The company develops adeno-associated virus based gene therapies using its gene technology platform. UniQure offers clinical and preclinical programs for lipoprotein lipase deficiency, hemophilia A and B, Huntington’s disease, …
  • Achelios Therapeutics Inc-製薬・医療分野:企業M&A・提携分析
    Summary Achelios Therapeutics Inc (Achelios) is a biopharmaceutical development company that provides reformulation of non-steroidal anti-inflammatory (NSAID) drug molecules. The company offers therapeutic entity development for the treatment of pain and inflammation. Its lead product includes Topof …
  • Glenmede Corporation:企業の戦略・SWOT・財務情報
    Glenmede Corporation - Strategy, SWOT and Corporate Finance Report Summary Glenmede Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆